Welcome to our dedicated page for Kamada SEC filings (Ticker: KMDA), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Kamada Ltd. filings document a foreign private issuer reporting on a global biopharmaceutical business focused on specialty plasma-derived therapies and marketed products for rare and serious conditions. Recent Form 6-K reports include exhibits on financial results, annual guidance, investor presentations, product-supply tenders, and FDA approval of a plasma collection center.
The filings also record ordinary-share dividend actions, withholding-tax procedures tied to Israeli tax rules, and incorporation of certain current reports by reference into Form S-8 registration statements. Kamada files as a Form 20-F issuer, with disclosures covering governance, capital-return actions, commercial portfolio performance and regulatory events affecting plasma collection and product supply.
Kamada Ltd. is calling an Annual General Meeting of Shareholders for August 5, 2026 in Rehovot, Israel, with a June 23, 2026 record date. Shareholders will vote on re-electing seven directors and two external directors, option grants to all director nominees, and an amendment to the 2011 Israeli Share Award Plan’s U.S. Taxpayers Appendix.
The amendment would lift the incentive stock option limit under the U.S. appendix from 500,000 to 550,000 ordinary shares. Investors will also vote on ratifying Kost Forer Gabbay & Kasierer (Ernst & Young Global member) as independent auditors for 2026, while management reviews 2025 financial statements with shareholders.
Kamada Ltd. reported that the FDA approved its new in-house Rapid Fluorescent Focus Inhibition Test (RFFIT) laboratory, used to measure rabies-neutralizing antibodies. The lab supports Anti-Rabies potency testing for the manufacture of the company’s Anti-Rabies immunoglobulin products KEDRAB and KAMRAB.
The RFFIT lab, located at Kamada’s Beit Kama plant in Israel, is part of its quality control network and is described as meeting stringent safety, quality and GMP standards. It was previously approved by Health Canada and the Israeli Ministry of Health. In 2025, sales of KEDRAB and KAMRAB together totaled over $70 million, making them a leading franchise in Kamada’s specialty plasma-derived portfolio.
Kamada Ltd. reported first quarter 2026 revenue of $45.2 million, up about 3% year-over-year, with net income of $4.1 million and adjusted EBITDA of $11.6 million, a solid 26% margin. Results were affected by a temporary shipment delay of a single order that shipped in April.
The company reaffirmed its 2026 guidance for revenue of $200–$205 million and adjusted EBITDA of $50–$53 million, which it notes imply 12% revenue growth and 23% adjusted EBITDA growth versus 2025 midpoints. Management expects a significantly stronger remainder of 2026 driven by its six FDA-approved plasma-derived products, expanding biosimilar distribution in Israel and MENA, and ramp-up of three U.S. plasma collection centers.
As of March 31, 2026, Kamada held $73.1 million in cash, cash equivalents and short-term investments. The board declared a $0.25 per share special cash dividend, totaling about $14.4 million, paid in April 2026.
Kamada Ltd. filed a Form 6-K to announce that it will release financial results for the first quarter ended March 31, 2026, before the U.S. market open on May 13, 2026. Management will host a conference call that day at 8:30am Eastern Time for investors and analysts.
The company is a global biopharmaceutical business focused on specialty plasma-derived therapies for rare and serious conditions. Its strategy centers on organic growth of its commercial portfolio, in-licensing and distribution in Israel and the MENA region, expanding plasma collection operations, and pursuing mergers, acquisitions, and collaboration opportunities. FIMI Opportunity Funds is the controlling shareholder, holding approximately 38% of the outstanding ordinary shares.
KAMADA LTD director Lilach Asher-Topilsky has filed an initial Form 3 detailing existing employee stock option holdings held by a trustee under the company’s 2011 Share Award Plan. The options relate to 6,625 underlying Ordinary Shares at an exercise price of $7.60 and 7,500 underlying Ordinary Shares at $6.17, with tranches vesting in four equal annual installments. The exercise prices were adjusted from $7.85 to $7.60 and from $6.42 to $6.17 following a cash dividend declared on March 11, 2026; no other award terms changed and no new buy or sell transactions are reported.
KAMADA LTD director Uri Botzer filed an initial ownership report showing indirect holdings of employee stock options over Ordinary Shares, held by a trustee under the company’s 2011 Share Award Plan. Each option position relates to 7,500 underlying Ordinary Shares with an exercise price of $5.50 per share and an expiration date of June 22, 2029.
The options vest in four equal installments, with 25% vesting on each of the four anniversaries of the grant date. The exercise price was adjusted from $5.75 to $5.50 under the plan following a cash dividend distribution declared on March 11, 2026. All exercise prices shown in U.S. dollars are convenience conversions from NIS using the Bank of Israel exchange rate as of April 16, 2026.
Kamada Ltd Vice President of Business Development and Strategic Programs, Boris Gorelik, reported routine compensation-related option adjustments held indirectly by a trustee under the company’s 2011 Share Award Plan. On April 7, 2026, he received several employee stock option awards, each for 3,750 Ordinary Shares at an exercise price of $9.13 per share, and returned options with the same share amount but a $9.38 exercise price to the issuer. Footnotes state the exercise prices are presented in U.S. dollars based on an exchange rate as of April 6, 2026, and were adjusted under the plan in connection with a cash dividend distribution, with no other changes to the option terms. These options vest in four equal 25% annual installments from the grant date and expire on February 11, 2027.
Kamada Ltd VP Human Resources Reshef Liron reported a series of option compensation adjustments involving employee stock options held by a trustee under the company’s 2011 Share Award Plan. The transactions combine option grants and corresponding dispositions back to the issuer with no net change in share count.
The filing shows multiple option awards over ordinary shares in blocks of 10,000 and 15,000, with exercise prices stated in U.S. dollars between $5.04 and $7.25, and corresponding adjustments from prior prices between $5.29 and $7.50. All options vest in four equal annual installments from each grant date and carry expirations between 2029 and 2035, reflecting routine compensation and price adjustments following a cash dividend.
Kamada Ltd Chief Executive Officer Amir London reported a series of compensation-related option changes, not open-market trading. A trustee under Kamada’s 2011 Share Award Plan received several grants of employee stock options for 100,000 ordinary shares each at exercise prices such as $5.87 and $7.25, while matching 100,000-option awards at $6.12 and $7.50 were returned to the company.
According to the notes, the exercise prices were adjusted under the 2011 Share Award Plan after a cash dividend declared on March 11, 2026, with no other changes to the award terms. The options vest in four equal annual installments and are held by a trustee under the plan.
Kamada Ltd director Karnit Goldwasser reported a series of employee stock option updates held indirectly through a trustee under the company’s 2011 Share Award Plan. The filing shows paired grant awards (code A) and dispositions back to the issuer (code D) in matching share amounts, leaving her net option position unchanged from these transactions.
The options cover Ordinary Shares with exercise prices converted from NIS, ranging from $5.87 to $7.48 per share and expirations between September 25, 2026 and June 22, 2029. A footnote explains the exercise prices were adjusted under the plan after a cash dividend declared on March 11, 2026, with no other changes to the award terms.